Market capitalization | $252.08m |
Enterprise Value | $205.53m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.92 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-23.40m |
Free Cash Flow (TTM) Free Cash Flow | $-21.24m |
Cash position | $47.25m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:
4 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.10 -0.10 |
64%
64%
|
|
EBITDA | -23 -23 |
22%
22%
|
EBIT (Operating Income) EBIT | -23 -23 |
23%
23%
|
Net Profit | -23 -23 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
Head office | United States |
CEO | Richard Miller |
Employees | 28 |
Founded | 2014 |
Website | www.corvuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.